A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Recruiting now · Phase 3
Conditions studied: Relapsed and/or Refractory Multiple Myeloma (RRMM)
In brief
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Key facts
- Study ID
- NCT07222761
- Run by
- Regeneron Pharmaceuticals
- People needed
- 915
- Starts
- 2026-01-02
- Expected to finish
- 2034-08-23
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- OhioHealth — Columbus, Ohio, United States (enrolling)
- University of Texas Health Science Center, Houston — Houston, Texas, United States (enrolling)
- Mater Misericordiae Ltd — Brisbane, Queensland, Australia (enrolling)
- Gold Coast Hospital and Health Service — Southport, Queensland, Australia (enrolling)
- Alfred Hospital — Melbourne, Victoria, Australia (enrolling)
- Chonnam National University Hwasun Hospital — Hwasun, Jeollanam-do, South Korea (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- Severance Hospital; Division of Hematology — Seoul, South Korea (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Seoul St. Mary's Hospital, The Catholic University of Korea — Seoul, South Korea (enrolling)
- Ulsan University Hospital — Ulsan, South Korea (enrolling)
- Aberdeen Royal Infirmary — Aberdeen, Aberdeenshire, United Kingdom (enrolling)
- Royal Cornwall Hospital National Health Service (NHS) Foundation Trust — Truro, Cornwall, United Kingdom (enrolling)
- University Hospitals Plymouth National Health Service (NHS) Foundation Trust - Hematology — Plymouth, Devon, United Kingdom (enrolling)
- Norfolk and Norwich University Hospital National Health Service (NHS) Foundation Trust — Norwich, Norfolk, United Kingdom (enrolling)
- University Hospitals Birmingham NHS Trust, Center for Clinical — Birmingham, West Midlands, United Kingdom (enrolling)
- Ninewells Hospital and Medical School — Dundee, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.